NYSE American listing for Israel companies.
The NYSE market designed for earlier-stage and small-cap companies. A reverse takeover reaches NYSE American by merging into a listed shell or uplisting once the standards are met.
For a private company in Israel, NYSE American can be reached through a reverse takeover — the merger of the operating business into a shell company — provided the applicable listing standards are met.
- A Israel company can reach NYSE American by merging into a listed shell, or by uplisting to it from a lower tier once the standards are met.
- NYSE American sets several qualification standards based on pre-tax income, market capitalisation, or total assets and revenue, together with public-float, shareholder, and minimum-price requirements and NYSE corporate-governance rules.
- US-standard audited financials from a PCAOB-registered auditor are required, and are usually the critical-path item.
- Reverse Takeover arranges and coordinates the transaction; the regulated work is done by licensed specialists.
The route in brief
| Venue | NYSE American — NYSE American |
|---|---|
| Route | Reverse takeover into a listed shell, or uplisting from a lower tier once standards are met. |
| Standards | NYSE American sets several qualification standards based on pre-tax income, market capitalisation, or total assets and revenue, together with public-float, shareholder, and minimum-price requirements and NYSE corporate-governance rules. |
| Home market | Tel Aviv Stock Exchange (TASE) · regulator ISA |
| Currency | Israeli shekel (ILS) |
| Our role | Advisory and arranger; not a broker-dealer, law firm or auditor. |
NYSE American for Israel companies
NYSE American matters for Israeli issuers chiefly as the venue for companies not yet at Nasdaq’s thresholds — clinical-stage medical-device and biotech businesses, and small-cap technology companies whose float is still forming. The exchange’s small-cap market publishes several alternative qualification routes, and the minimum price under some of them sits below Nasdaq’s US$4.00, which can spare an Israeli company a consolidation at exactly the moment a consolidation would be read as weakness. The public-shareholder and public-float conditions are what bind first.
The distinctly Israeli constraint sits upstream of the exchange entirely. Companies that have received grants from the Israel Innovation Authority are subject to restrictions on transferring funded know-how outside Israel, and to notification and approval requirements on a change of control. Where a listing structure contemplates a US or offshore top company above the Israeli operating entity, the Innovation Authority position has to be established before the structure is fixed. It can determine that the Israeli company must remain the owner of the technology, which in turn shapes what the US-quoted parent actually holds and how investors should be told to value it. This is a question for Israeli counsel, and it is discovered late far too often.
The audit path is comparatively straightforward. Israeli practices of the global network firms hold PCAOB registration and routinely produce US-form financial statements, and the PCAOB’s international oversight programme covers non-US firms auditing US issuers. The constraint is the form of the statements rather than access to an auditor: the required comparative periods, and the separate accounts of any business acquired in or around the transaction, are what set the calendar. What typically goes wrong on this venue is that an Israeli company treats NYSE American as a waiting room for Nasdaq without building the uplisting conditions into its financing plan, and then finds the float and price tests unmet at the moment it wants to move.
Structuring a reverse takeover from Israel
Cross-border structuring is unusually well-trodden for Israeli companies. Many operate through an Israeli parent that can itself be the US-quoted entity. Others use a Delaware or Cayman top company set up for the listing. Both patterns are routine, and Israeli and US counsel coordinate them regularly. Israel does not impose the outbound-investment or exchange-control frictions seen in some emerging markets. Moving to a US-quoted structure is therefore generally about corporate, securities, and tax mechanics rather than regulator approvals. Several points should be mapped early. These include Israeli tax on any share exchange or corporate migration, the treatment of employee option pools (a significant feature of Israeli tech compensation), and Israel Securities Authority (ISA) considerations if a TASE listing is contemplated. This is educational; specific structures should be set with counsel.
Considering NYSE American for your Israel company?
Start an enquiry →NYSE American listing for Israel companies — FAQ
Q1Can a Israel company list on NYSE American via reverse takeover?
A Israel company can reach NYSE American by merging into a shell already listed there, or by uplisting once it meets the applicable standards. NYSE American sets several qualification standards based on pre-tax income, market capitalisation, or total assets and revenue, together with public-float, shareholder, and minimum-price requirements and NYSE corporate-governance rules.
Q2What are the NYSE American listing standards?
NYSE American sets several qualification standards based on pre-tax income, market capitalisation, or total assets and revenue, together with public-float, shareholder, and minimum-price requirements and NYSE corporate-governance rules. Meeting these standards, and maintaining them, is assessed with US securities counsel as part of the transaction.
Q3Is Reverse Takeover a broker-dealer?
No. Reverse Takeover is an advisory and arranger, not a registered broker-dealer, law firm or auditor. Regulated activities are performed by licensed US securities counsel, PCAOB-registered auditors, transfer agents and broker-dealers coordinated on the transaction.
Other US venues for Israel companies
- Nasdaq listingIsrael → Nasdaq
- OTC Markets listingIsrael → OTC Markets
- Israel — all routesCountry overview
This page is general, educational information about listing routes and is not investment, legal, tax, or accounting advice, nor an offer or solicitation. Regulatory details change and vary by circumstance; obtain advice from qualified US securities counsel and your home-market advisers. See our disclosures.